ADT Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James D. DeVries
- Full Time Employees
- 12,200
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 1501 Yamato Road Boca Raton FL United States 33431
- IPO Date
- Jan 19, 2018
- CIK
- 0001703056
- Website
- adt.com
- Similar Companies
- Business
- ADT Inc. (NYSE: ADT) provides residential, small business, and commercial security and smart home solutions throughout the United States and Canada; core offerings encompass professionally monitored burglar alarms, life safety systems including fire, smoke, and carbon monoxide detection, smart security cameras, video surveillance, access control, medical alert services with fall detection and GPS tracking, identity theft protection, secure Wi-Fi solutions, and cybersecurity consulting; the company delivers integrated platforms such as the ADT+ smart home security system featuring proprietary hardware, software, Google Nest device integration, AI-powered insights, real-time alerts, and single-app control for alarms, cameras, smart locks, lights, and thermostats, alongside Trusted Neighbor technology enabling secure, timed access for trusted individuals via Yale smart locks and Nest doorbells with auto-unlock capabilities; additional services include Remote Assistance for troubleshooting without on-site visits and customized solutions for enterprises like enterprise-level monitoring, reporting, and fire protection. Founded in 1874 as American District Telegraph in Baltimore, Maryland, and headquartered at 1501 Yamato Road in Boca Raton, Florida, ADT operates over 150 locations with more than 13,000 professionals serving over 6 million customers. Recent developments include the 2024 launches of the ADT+ platform and Trusted Neighbor feature, expansion of ADT Safe Places partnerships with nonprofits for community safety, a bulk account acquisition worth $89 million in Q2 2025 yielding favorable returns, ongoing State Farm partnership for customer growth targeting movers, new veteran hiring initiatives with Oplign and Orion Talent across 16 military bases and 30 career fairs, a $300 million loan facility secured in October 2025 to bolster liquidity and growth amid competition, and Q3 2025 results showing 4% revenue growth driven by recurring monthly revenue despite market pressures.
Company News
ADT: 3 Key Takeaways for Long-Term Investors
ADT Q3 Earnings Call Highlights
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - MSWV, ADT, CART and MFIC - IS IT A FAIR DEAL FOR YOU?
ADT Inc. (ADT) Q3 2026 Earnings Call Prepared Remarks Transcript
ADT (ADT) Matches Q3 Earnings Estimates
ADT Reports Third Quarter 2026 Results
ADT Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ADT Inc. - ADT
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)
Stock Market Today, Oct. 29: ADT Surges 33% on $10 Per Share All-Cash Acquisition Deal
OpenAI-backed Thrive Holdings acquires ADT
ADT SHAREHOLDER ALERT: Ademi LLP Investigates Whether $10 Buyout Fairly Values ADT INC
ADT Soars 34% on a $10 Buyout: What It Means for the ETFs That Own It
ADT Stock Alert: Halper Sadeh LLC is Investigating Whether ADT Inc. is Obtaining a Fair Price for its Shareholders
Josh Kushner's Thrive to Buy ADT for $7.6 Billion
ADT (ADT) Soars 7.9%: Is Further Upside Left in the Stock?
ADT to be Acquired by Thrive Holdings in $15.3 Billion Transaction
On National First Responders Day, ADT Honors Those Who Answer the Call and Unveils Renovated North Texas Monitoring Center
ADT Secures AI Innovation with Oracle
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer